Related Experiment Videos
Neuroendocrine effects of setoperone: a new neuroleptic drug
Abstract:
Setoperone (R 52245), a serotonin S2 and dopamine D2 receptor blocker, was tested on eight healthy male volunteers, receiving 5 or 40 mg orally, in order to assess the modifications of plasma prolactin levels, as an index of receptor blocking activity. Both doses significantly increased plasma levels, confirming the dopamine blocking activity. In vitro and in vivo studies have shown serotonin S2 receptor blockade and lysergic acid diethylamide antagonist activity. Setoperone is proposed as a possible new neuroleptic drug.
Insights
Setoperone, a novel drug, effectively blocks dopamine D2 receptors, as shown by increased prolactin levels in healthy volunteers. It also exhibits serotonin S2 receptor antagonism, suggesting potential as a new neuroleptic medication.
Area of Science:
- Pharmacology
- Neuroscience
- Clinical Medicine
Background:
- Setoperone (R 52245) is a compound investigated for its receptor-binding properties.
- Understanding its effects on neurotransmitter systems is crucial for therapeutic development.
Purpose of the Study:
- To evaluate the dopamine D2 and serotonin S2 receptor blocking activity of Setoperone in humans.
- To assess the impact of Setoperone on plasma prolactin levels as a biomarker for dopamine D2 receptor blockade.
Main Methods:
- A double-blind, placebo-controlled study involving eight healthy male volunteers.
- Oral administration of Setoperone at two doses: 5 mg and 40 mg.
- Measurement of plasma prolactin levels to assess dopamine D2 receptor antagonism.
Main Results:
- Both 5 mg and 40 mg doses of Setoperone significantly elevated plasma prolactin levels.
- This increase in prolactin confirms the drug's dopamine D2 receptor blocking activity.
- In vitro and in vivo data indicated serotonin S2 receptor blockade and lysergic acid diethylamide antagonist effects.
Conclusions:
- Setoperone demonstrates significant dopamine D2 receptor blockade in humans.
- The drug exhibits serotonin S2 receptor antagonism.
- Setoperone shows promise as a potential new neuroleptic agent.